Initiation: Scaffold in place for future growth
Avacta Life Sciences (ALS) is pioneering the commercialisation of antibody-like protein scaffold technology for research and therapeutic use. Affimers have a range of performance benefits over the gold standard antibodies, making them a potentially disruptive technology. Avacta would need only a small share of the estimated $1bn research antibodies market to support its valuation, with upside potential from therapeutic licensing. We forecast that Avacta Life Sciences will drive the group to profitability, forecast in 2017. Our valuation of Avacta Group is £54m.Avacta Group is a biotechnology company that is developing biotherapeutics and reagents based on its proprietary Affimer technology, an engineered alternative to antibodies. Affimer® reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a range of applications where antibodies and aptamers have limitations. Co. has two operating segments: Life Sciences, which provides custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development; and Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.